A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects (clinicaltrials.gov) - Jul 5, 2023 - P1 | N=21 | Completed | Sponsor: Endeavor Biomedicines, Inc. | Recruiting ➔ Completed
Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|